TOP STORY Scientists Make Significant Type 2 Diabetes Breakthrough Scientists have found that the peptide hormone, islet amyloid polypeptide, which gets deposited in the pancreas in type 2 diabetes, is the trigger for a protein complex called the inflammasome. [Press release from Trinity College Dublin discussing online prepublication in Nature Immunology]
|
|
INDUSTRY NEWS STEMSOFT® Software Inc. Licenses StemLab® Software to Arizona’s Celebration Stem Cell Centre STEMSOFT Software Inc., the leading provider of software solutions for the cell therapy and transplant community, is pleased to announce the licensing of StemLab, the leading cell therapy and cord blood banking laboratory software, to the Celebration Stem Cell Centre in Gilbert, Arizona. [STEMSOFT Software Inc. Press Release] AstraZeneca and UCL Join Forces in Sight-Related Stem Cell Medicine AstraZeneca and University College London (UCL) have entered into a collaboration to develop regenerative medicines for diabetic retinopathy. [University College London Press Release] The Pancreatic Cancer Action Network and AACR to Award Nearly $3 Million in Pancreatic Cancer Research Grants The American Association for Cancer Research in partnership with the Pancreatic Cancer Action Network is now accepting applications for the 2011 research grants program. [American Association for Cancer Research Press Release] Forbion Capital Partners Raises EUR190 Million for New Investments Forbion Capital Partners, a leading investment firm dedicated to the life science sector, announced the final closings of both FCF I Co-Invest Fund and of FCF II, raising a total of more than EUR190 million ($240 million). [Forbion Capital Partners Press Release] Lilly to Invest Up to $150 Million in Venture Capital Eli Lilly & Co., facing competition from cheaper copies of its top-selling drug next year, plans to invest as much as $150 million in three venture capital funds to aid development of new medicines. [Bloomberg] Santarus Licenses Novel Type 2 Diabetes Drug CYCLOSET Santarus, Inc., S2 Therapeutics, Inc. and VeroScience LLC announced that they have entered into a distribution and license agreement granting Santarus exclusive rights to manufacture and commercialize CYCLOSET® (bromocriptine mesylate) tablets in the U.S. [Santarus Inc. Press Release] After Adverse Effects, Roche Ends Trials of Diabetes Drug Roche has ended late-stage clinical trials that involved giving patients its experimental diabetes treatment taspoglutide. [American Diabetes Association Press Release]
|
|
POLICY NEWS Appeals Court Stays Stem Cell Injunction A federal appeals court stayed, or suspended, a preliminary injunction issued two weeks ago that brought federal funding for human embryonic stem cell research to a standstill. [Court of Appeals, United States] NIH Rushes to Hand Out Stem Cell Grants During Temporary Stay The National Institutes of Health (NIH) is scrambling to push out research grants for work on human embryonic stem cells (hESCs) and has given a cautious all-clear to in-house stem cell researchers after an appeals court yesterday temporarily lifted a ban on federal funding for hESC research. [National Institutes of Health, United States] NIH Expands Network Focused on How Genes Affect Drug Responses The National Institutes of Health plans to spend $161.3 million over the next five years to expand the Pharmacogenomics Research Network, a nationwide collaborative of scientists focused on understanding how genes affect a person’s response to medicines. [National Institutes of Health, United States] Funds Awarded for Disease Demonstration Studies and Technology Development The National Institutes of Health announced it has awarded approximately $42 million to expand the scope of eight demonstration projects designed to link changes in the human microbiome to health and disease. [National Institutes of Health, United States] ‘Sound Science’ Code Draws Fire The first draft policy on scientific integrity from a federal agency, released by the Department of the Interior, has drawn a storm of criticism from watchdogs including the Union of Concerned Scientists, based in Cambridge, Massachusetts. [Union of Concerned Scientists, United States] Diabetes – Liraglutide: Final Appraisal Determination After considering the feedback from consultation, the Appraisal Committee has prepared a Final Appraisal Determination on liraglutide for the treatment of type 2 diabetes mellitus and submitted it to the Institute. [National Institute for Health and Clinical Excellence, United Kingdom] European Medicines Agency Update on Ongoing Benefit-Risk Review of Avandia, Avandamet and Avaglim The European Medicines Agency is currently reviewing rosiglitazone to determine the impact of new data from recent publications on the risk of cardiovascular problems on the benefit- risk profile of these medicines. [European Medicines Agency, European Union] New Animal-Research Regulations for the European Union European scientists will use fewer animals in research when newly approved regulations come into effect across the European Union. [European Parliament, European Union] NIH Statement Regarding Stay of Stem Cell Injunction [National Institutes of Health, United States] National Institute of Diabetes and Digestive and Kidney Diseases; Notice of Closed Meetings (FR Doc. 2010-22527) [National Institutes of Health, United States] Participation of National Institute of Diabetes and Digestive and Kidney Diseases on PAR-10-266, Support of NIGMS Program Project Grants (P01) (NOT-DK-10-012) [National Institute of Diabetes and Digestive and Kidney Diseases, United States] National Institute of Biomedical Imaging and Bioengineering; Notice of Closed Meeting (FR Doc. 2010-22327) [National Institutes of Health, United States] National Center for Research Resources; Notice of Closed Meetings (FR Doc. 2010-22529) [National Institutes of Health, United States] Enhancing Peer Review: Reminder of and Correction to Previous Notice on A2 Resubmission Opportunities for Eligible Applications (NOT-OD-10-135) [National Institutes of Health, United States] Notice of Correction to RFA-AG-11-010, Basic Research on Self-Regulation (R21) (NOT-AG-10-011) [National Institutes of Health, United States] Public Meeting on Animal Models–Essential Elements to Address Efficacy Under the Animal Rule; and Reopening of Comment Period (Docket No. FDA-2009-D-0007) [Food and Drug Administration, United States]
|
|
EVENTS (Listed by Date) NEW Third Annual Maryland Stem Cell Research Symposium September 22, 2010 Gaithersburg, United States Annual Human Proteome Organization (HUPO) World Congress September 19-23, 2010 Sydney, Australia 46th European Association for the Study of Diabetes Annual Meeting September 20-24, 2010 Stockholm, Sweden Institute of Medicine – University of Illinois at Chicago Midwest Conference on Diabetes and Obesity September 21, 2010 Chicago, United States 35th European Society for Medical Oncology (ESMO) Congress October 8-12, 2010 Milan, Italy Fraunhofer Life Science Symposium 2010 October 29-30, 2010 Leipzig, Germany 2010 American Pancreatic Association (APA) Annual Meeting November 3-6, 2010 Chicago, United States Select Biosciences International Forum on Stem Cells November 12-13, 2010 Tianjin, China Australasian Pancreatic Club Annual Meeting November 15-16, 2010 Melbourne, Australia Type 2 Diabetes, Insulin Resistance and Metabolic Dysfunction January 12-17, 2011 Keystone, United States 2011 Gastrointestinal Cancers Symposium January 20-22, 2011 San Francisco, United States Epithelial Plasticity and Epithelial to Mesenchymal Transition January 21-26, 2011 Vancouver, Canada Select Biosciences 5th Annual Stem Cells and Regenerative Medicine World Congress January 24-25, 2011 San Diego, United States Phacilitate 7th Annual Cell & Gene Therapy Forum 2011 January 24-26, 2011 Washington, DC, United States Joint Conference of the International Association of Pancreatology and the Indian Pancreas Club February 10-13, 2011 Maradu, India Visit our events page to stay up to date with the latest events in the cell, gene and immunotherapy community.
JOB OPPORTUNITIES Cell Therapy Technologist (Opexa Therapeutics) Recruit Top Talent Reach more than 11,000 potential candidates by posting your organization’s career opportunities with Cell Therapy News. Visit here to post your career opportunities.
Have we missed an important article or publication in Pancreatic Cell News? Click here to submit! |
| |
|